🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥

Startup Showcase

Premium Content

Try our Valuation Calculator →

News on Medial

Q3 Results Today: ZEEL, HAL, GlaxoSmithKline Pharma and more to post earnings

Livemint

Livemint · 1y ago

Q3 Results Today: ZEEL, HAL, GlaxoSmithKline Pharma and more to post earnings

Today, on February 12, over 480 companies including Coal India Ltd, GlaxoSmithKline Pharmaceuticals Ltd, Hindustan Aeronautics Ltd, Maruti Infrastructure Ltd, TCI Express Ltd, and Zee Media Corporation Limited are scheduled to announce their quarter 3 results. The BSE Sensex and Nifty 50 both experienced positive movements on February 9, with support levels and resistance levels identified. Additionally, various other companies are set to release their quarterly results today.

Related News

Q3 Results Today: M&M, NMDC, Muthoot Finance, ABFRL to post earnings on Feb 14

Livemint

Livemint · 1y ago

Q3 Results Today: M&M, NMDC, Muthoot Finance, ABFRL to post earnings on Feb 14

On February 14, several top companies including Mahindra & Mahindra, NMDC, Muthoot Finance, Natco Pharma, Indiabulls Housing Finance, and Shriram Properties are scheduled to announce their Q3 results. The benchmark indices showed recovery on February 13, with BSE Sensex gaining 483 points and Nifty 50 increasing by 127 points. Market volatility is expected to persist due to factors like geopolitical concerns, stretched valuations, and FII selling. Over 30 major companies are set to announce their earnings on February 14.

Q3 results next week: HAL, SAIL, ONGC, IRCTC, M&M among others to declare

Livemint

Livemint · 1y ago

Q3 results next week: HAL, SAIL, ONGC, IRCTC, M&M among others to declare

Next week will see several big companies releasing their quarterly financial results. Some of the notable ones include Hindustan Aeronautics Limited, ONGC, IRCTC, and Mahindra & Mahindra. Over 450 companies from various sectors will be disclosing their financial results in the coming week. The earnings season, which started with Infosys and TCS, now shifts focus to heavyweight players across different industries. For the full list of companies scheduled to announce their earnings, refer to the provided URL.

Q3 Results Today: Siemens, Eicher Motors, BHEL, IRCTC and more to post earnings

Livemint

Livemint · 1y ago

Q3 Results Today: Siemens, Eicher Motors, BHEL, IRCTC and more to post earnings

Several major companies across various sectors, including Siemens, Hindalco Industries, Eicher Motors, BHEL, and Zee Entertainment Enterprises, are set to report their Q3 earnings today. The Indian stock market experienced a decline on February 12, primarily due to selling pressure in banking & financial services, metal, FMCG, and oil & gas stocks. Around 34 companies are scheduled to post earnings on February 13, with Livemint being recognized as the fastest-growing news website in the world. Finance Minister Nirmala Sitharaman's Budget speech is also summarized.

Q3 Results Today: Ballarpur Ind, Hardwyn India, R Systems and more

Livemint

Livemint · 1y ago

Q3 Results Today: Ballarpur Ind, Hardwyn India, R Systems and more

Companies such as Ballarpur Industries Ltd, EPACK Durable Ltd, Hardwyn India Ltd, R Systems International Limited, and Shivom Investment & Consultancy Ltd are scheduled to announce their Q3 results on February 15. This comes as the earnings season nears its end, with over 620 companies having already announced their December quarter earnings on February 14. The Indian stock market witnessed a rebound on February 14, with the BSE Sensex closing higher by 268 points and the Nifty 50 gaining 97 points.

Infosys expected to report weak Q3 earnings with drop in revenue, margins

Livemint

Livemint · 1y ago

Infosys expected to report weak Q3 earnings with drop in revenue, margins

Infosys is expected to announce weak Q3 results, with a sequential drop in revenues and margins. The overall Indian IT sector is also expected to report subdued earnings for the quarter due to weak demand. However, better utilization, lower sub-con expenses, and INR depreciation may help offset some of the challenges for Infosys. The company's Q3 revenue in USD terms is predicted to decline, while net profit is expected to drop slightly. Analysts anticipate Infosys to maintain its guidance for FY24 growth.

IM Capitals Q3 FY24 Results Live : profit rise by 2227.97% YOY

Livemint

Livemint · 1y ago

IM Capitals Q3 FY24 Results Live : profit rise by 2227.97% YOY

IM Capitals reported impressive Q3 FY24 results, with a 653.75% YoY increase in revenue and a staggering 2227.97% YoY growth in profit. Although revenue dipped slightly by 5.09% from the previous quarter, the company managed to boost its profit by 5.77%. Operating income also showed strong growth, with a 292.06% QoQ increase and a 1593.66% YoY increase. The Earnings Per Share (EPS) for Q3 FY24 stood at ₹46.94, marking a notable growth of 792.4% YoY. IM Capitals' market performance has been positive, with returns of 17.13% over the past 6 months.

Ecom Express Buyout Expands Delhivery’s Market Share By 25%

Inc42 · 27d ago

Ecom Express Buyout Expands Delhivery’s Market Share By 25%

Delhivery's acquisition of competitor Ecom Express has expanded its market share by 25%, according to CEO Sahil Barua. During a Q1 earnings call, Barua noted that Delhivery retained 50-55% of Ecom Express' volume, surpassing the expected 30%. The acquisition impact on Delhivery's Q1 financials was minimal since volume growth appeared late in June. The integration cost of INR 300 Cr will affect financial results in Q2 and Q3.

PB Fintech posts Rs 1,292 Cr revenue and Rs 72 Cr profits in Q3 FY25

Entrackr

Entrackr · 7m ago

PB Fintech posts Rs 1,292 Cr revenue and Rs 72 Cr profits in Q3 FY25

PB Fintech’s revenue increased to Rs 1,292 crore in Q3 FY25 as compared to Rs 871 crore during Q3 FY24, as per the firm’s unaudited consolidated financial results. PB Fintech, the parent company of Policybazaar and Paisabazaar, recorded a 48.3% year-on-year increase in revenue during the third quarter of the ongoing fiscal year (FY25). At the same time, the firm nearly doubled its profits, maintaining strong growth in earnings. Insurance broking formed 87.6% of the total collections which surged by 62.4% to Rs 1,132 crore during Q3 FY25 from Rs 697 crore in Q3 FY24. The income from other operating activities, which include marketing, advertising, consulting, and support services, plunged 8% to Rs 160 crore in the same period. The firm earned Rs 100 crore from non-operating activities including financial income, tallying its overall revenue to Rs 1,392 crore in Q3 FY25, compared to Rs 965 crore in the same quarter of the previous fiscal year. For PB Fintech, employee benefits cost remained the largest cost center forming 37% of the overall expenditure. This cost increased by 22.4% YoY to Rs 487 crore in Q3 FY25 from Rs 398 crore in Q3 FY24. This includes Rs 51 crore as ESOP expense (non-cash). The company’s spending on advertising and promotional grew 34% to Rs 289 crore. Its network, internet, legal, rent, and other overheads pushed its total expenditure to Rs 1,307 crore in Q3 FY25 from Rs 926 crore in Q3 FY24. The significant year-on-year growth helped PB Fintech to post a 94.6% surge in profits to Rs 72 crore in Q3 FY25 from Rs 37 crore in the third quarter of the previous fiscal year. On a unit level, the Gurugram-based firm spent Rs 1.01 to earn a rupee in Q3 FY25. PB Fintech ended the day on January 30 with a share price of Rs 1,659.7 and a total market capitalization of Rs 76,225 crore (approximately $9 billion).

Pharma stocks & Trump tariff fears: Healthcare index down 6% in 5 days; selloff justified?

Business Today

Business Today · 6m ago

Pharma stocks & Trump tariff fears: Healthcare index down 6% in 5 days; selloff justified?

The recent selloff in pharma stocks triggered by fears of potential US tariffs on drug imports is seen as an unjustified reaction. Analysts view the current market weakness as a buying opportunity, anticipating strong earnings growth ahead at attractive valuations. Despite concerns, shifting some pharma manufacturing to the US may not significantly impact the sector. The market outlook remains optimistic, with experts recommending investment in the resilient pharma space.

Best pharma stocks to buy today as recommended by expert Raja Venkatraman

Livemint

Livemint · 2m ago

Best pharma stocks to buy today as recommended by expert Raja Venkatraman

Market expert Raja Venkatraman recommends three pharma stocks to watch on 16 June, noting significant growth and innovation within the Indian pharmaceutical sector. The sector is experiencing a shift from generic drugs to more innovative products and global expansion, with recent robust performance and a promising outlook.

Trackers

Active Indian VC’s

OG Capital Email

With a hands-on approach, OG Capital aims to invest in over 20 promising...

Accel Partners Email

Early and growth-stage investments in disruptive technology companies with...

Early-stage venture capital firm investing in technology startups in India. Focus on...

Access All Trackers

Startup Showcase Winners

June 2025

Helping your parents when you are miles away

The Pit Stop Your Cravings Deserve

The next generation E-commerce platform

Enter Ongoing Startup Showcase

Top Users

Trending News on Medial

Just Months After Promotion, Open ...

Microsoft locks down a building a ...

Gaming Ban Stumps Cricket: Virat ...

Download the medial app to read full posts, comements and news.